Lantheus Holdings Announces Presentations Featuring its PSMA-Targeted Pipeline Product Candidates at the 2021 ASCO GU Annual Meeting

Rhea-AI Summary

Lantheus Holdings, Inc. (NASDAQ: LNTH) announced that three abstracts related to its PSMA-targeted product candidates will be presented at the 2021 ASCO GU Virtual Meeting on February 11-13, 2021. These include two studies on PyL™, a PET/CT imaging agent for prostate cancer, and one on 1095, a radiopharmaceutical for metastatic castration-resistant prostate cancer. The studies focus on the efficacy and safety of these agents, showcasing Lantheus's commitment to advancing prostate cancer diagnostics and therapeutics.

Positive

• Three abstracts selected for presentation at ASCO GU, highlighting the PSMA-targeted pipeline.
• Focus on innovative agents for prostate cancer, potentially enhancing Lantheus's market position.

Negative

• None.

Lantheus Holdings, Inc. (NASDAQ: LNTH) (the “Company”), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, announced today three abstracts featuring its PSMA-targeted pipeline of product candidates have been selected for poster presentations at the upcoming 2021 American Society for Clinical Oncology Genitourinary (ASCO GU) Virtual Meeting, which will be held from February 11-13, 2021. Two of the abstracts relate to PyL™, the Company’s PET/CT imaging agent for prostate cancer, and the third abstract relates to 1095, the Company’s radiopharmaceutical therapeutic for metastatic castration resistant prostate cancer.

The presentations will be made available for the duration of conference.

Details for the ASCO GU presentations based on Company-sponsored studies are as follows:

Date & Time: February 11, 2021, 8:00 AM-6:30 PM ET
Session Title: Poster Session: Prostate Cancer – Advanced Disease
Title: A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.
Presenter: Jeremy C. Durack, M.D., M.S., Memorial Sloan Kettering Cancer Center
Abstract No: 32

Date & Time: February 11, 2021, 8:00 AM-6:30 PM ET
Session Title: Poster Session: Prostate Cancer – Advanced Disease
Title: PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR) - A sub analysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.
Presenter: Frederic Pouliot, M.D., Ph.D., F.R.C.S.C., Centre Hospitalier Universitaire (CHU) de Québec-Université Laval
Abstract No: 33

Date & Time: February 11, 2021, 8:00 AM-6:30 PM ET
Session Title: Trials in Progress Poster Session: Advanced Prostate Cancer
Title: A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).
Presenter: Oliver Sartor, M.D., Tulane Cancer Center
Abstract No: TPS187

About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY^® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite^® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA^® for the treatment of certain rare neuroendocrine tumors; and RELISTOR^® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada, and Sweden. For more information, visit www.lantheus.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210204005162/en/

FAQ

What presentations will Lantheus Holdings feature at the ASCO GU 2021?

Lantheus will present three abstracts related to its PSMA-targeted pipeline, including studies on PyL™ and 1095.

When is the ASCO GU 2021 meeting taking place?

The ASCO GU 2021 Virtual Meeting will be held from February 11-13, 2021.

What is the focus of the presentations by Lantheus at ASCO GU 2021?

The presentations will focus on prostate cancer diagnostics and therapies, including studies on 18F-DCFPyL-PET/CT and radioligand therapy.

What are the key studies being presented by Lantheus Holdings?

Key studies include a phase II/III study of PSMA-targeted imaging and a phase II study on the efficacy of radioligand therapy for metastatic prostate cancer.